AUTOLOGOUS ACTIVATED MONOCYTES GIVEN T P FOR COLONIC CARCINOMATOSIS

分离纯化的人单核细胞 外周血液已被证明能够杀死 细胞毒激活后肿瘤靶点的体外研究 干扰素-伽马。这项研究的目的是确定 自体激活的单核细胞可作为一种有效的 结肠癌患者的过继免疫治疗 扩散到腹膜腔。该协议基于 先前采用类似研究设计的BRMP协议； 然而，患者群体接受了剖腹手术和 完全手术切除所有肉眼肿瘤。病人们 在该方案中容忍白细胞分离和输注活化的 单核细胞和干扰素-伽马，毒性可耐受。 这项研究将招募具有可测量的宏观指标的患者。 疾病以确定过继转移是否激活 单核细胞对已建立的肿瘤具有杀伤活性。 由于这种疾病仅限于腹膜腔，因此 输注的单核细胞将与肿瘤有充分的接触 存款和贩运问题不应使 对其疗效进行分析。 尽管该方案过去一直对患者开放进入 年，没有病人登记参加方案，因为 存在相互竞争的方案，在腹膜内使用 注射白细胞介素2+LAK细胞。现在这个协议已经 已关闭，预计患者应计费用将为 对未来两年的这项研究具有重要意义。

Human monocytes that have been isolated and purified from the peripheral blood have been demonstrated to be capable of killing tumor targets in vitro following activation to cytotoxicity by interferon-gamma. The purpose of this study is to determine if autologous activated monocytes can be used as an effective form of adoptive immunotherapy for colon cancer patients with disease spread to the peritoneal cavity. This protocol is based on a previous BRMP protocol which employed a similar study design; however, the patient population had undergone laparotomy and complete surgical excision of all macroscopic tumor. The patients in that protocol tolerated leukapheresis and infusions of activated monocytes along with interferon-gamma with tolerable toxicity. This study will enroll patients who have measurable macroscopic disease to determine whether adoptively transferred activated monocytes have cytocidal activity against established tumor. Because the disease is limited to the peritoneal cavity, the infused monocytes will have adequate contact with the tumor deposits, and questions of trafficking should not complicate the analysis of their efficacy. Although the protocol has been open to patient entry for the past year, no patients were enrolled on the protocol due to the existence of a competing protocol using intraperitoneally administered interleukin-2 plus LAK cells. Now that protocol has been closed, it is expected that patient accrual will be significant for this study over the next two years.